Greg Slabodkin
Editor-in-Chief at Pharma Manufacturing
News Editor at #BioSpace #biopharma, #pharma, #biotechnology, #bigpharma, #pharmaceuticals
Articles
-
4 days ago |
pharmamanufacturing.com | Greg Slabodkin
Driven by the growing demand for new diabetes and obesity drugs, contract development and manufacturing organization CordenPharma Group — with 11 facilities across Europe and the United States — is looking to increase its peptide production capacity. The CDMO plans to invest more than €1 billion over the next three years to build and expand small, medium, and large manufacturing facilities in Europe and the U.S. to meet the needs of customers for both injectable and oral peptides.
-
4 days ago |
pharmamanufacturing.com | Greg Slabodkin
If the company secures regulatory approval, Eli Lilly will manufacture its weight-loss pill orforglipron in the United States, CEO David Ricks told Fox Business in a Friday interview — a day after the drugmaker reported Phase 3 trial results for the investigational oral GLP-1. While there have been shortages and supply constraints for injectable GLP-1 medicines, Ricks said it will be “easier” for Lilly to manufacture orforglipron at scale in the U.S. because it is an oral drug.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
The Trump administration’s announcement this week that the Department of Commerce has launched an investigation into U.S. reliance on pharmaceuticals and pharmaceutical ingredients made in other countries is widely seen as the precursor to pharma industry-specific tariffs, with the goal of encouraging domestic manufacturing.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
Thermo Fisher Scientific announced the opening of its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, California, which is meant to help biopharma, biotech, and translational customers accelerate their development and commercialization of cell therapies. While these potentially curative therapies offer hope to patients, the manufacturing and commercialization process remains complex and challenging.
-
1 week ago |
pharmamanufacturing.com | Greg Slabodkin
German pharma and lab equipment company Sartorius announced that it achieved significant profitable growth in the first quarter of 2025, with net profit jumping 21.4% and sales revenue increasing 7.7% in Q1 on a reported basis. Sartorius credited the “strong start to the year” to a nearly 10% revenue increase in the quarter for its Bioprocess Solutions division, which supports the manufacture of biopharmaceuticals.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 2K
- Tweets
- 9K
- DMs Open
- No
#Trump's #tariffs on #pharmaceuticals are coming. Now what? Despite Trump pushing #drugmakers to bring #manufacturing back to the US, it remains unclear whether companies — other than #EliLilly, J&J, and #Novartis — will respond. https://t.co/B70guBOMcj #pharmamanufacturing
#Novartis to invest $23 billion over five years on 10 US #manufacturing and R&D sites, including 7 new facilities. The announcement follows recent US manufacturing expansions by other #BigPharma companies including Eli Lilly and J&J. https://t.co/WnPJrfdtNz #pharmamanufacturing
#Cellares and the #UniversityofWisconsin are teaming to achieve clinical-scale production of UW-Madison's investigational #CRISPR-edited #CARTtherapy. The collaboration aims to automate the #manufacturing using Cellares' Cell Shuttle. https://t.co/DHWcEfMmYO #celltherapy #Madison